Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Dec
08
Today In Oncology
One in Three Families of Children With ALL Face Financial Hardship During Treatment
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
Non-Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo